Home Stock

Stock Research: Laboratorios Farmaceuticos Rovi

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Laboratorios Farmaceuticos Rovi

MCE:ROVI ES0157261019
98
  • Value
    50
  • Growth
    56
  • Safety
    Safety
    90
  • Combined
    82
  • Sentiment
    100
  • 360° View
    360° View
    98
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Laboratorios Farmaceuticos ROVI SA (ROVI) is a Spanish pharmaceutical company focused on the development and commercialization of medicines and drugs. It operates in Diagnostics (contrast mediums), Prescription (Hibor, Osseor, Hepadren, Pneumovax-23, Glufan, Corlentor, Exxiv, Calcio y Vitamina D3 Rovi, Absorcol), and Over The Counter (Perspirex, Enerzona, Dentimelo, ColdPack) fields. ROVI operates nationwide and abroad, with subsidiaries including Gineladius SL, Frosst Iberica SA, Rovi Contract Manufacturing SL, and Bertex Pharma GmbH. In the last fiscal year, the company had 2179 employees, a market cap of $3215 million, profits of $495 million, and revenue of $791 million.

more
Strongest Rank Capital Growth
Weakest Rank Sentiment
Country Spain
Industry Pharmaceuticals
Size Medium
Website rovi.es
Index
IBEX 35
Laboratorios Farmaceuticos Rovi stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 19-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
50 24 35 42
Growth
56 6 19 95
Safety
Safety
90 93 88 75
Sentiment
100 16 98 46
360° View
360° View
98 15 76 80
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
67 47 70 81
Opinions Change
90 12 69 50
Pro Holdings
n/a 32 90 12
Market Pulse
77 43 83 53
Sentiment
100 16 98 46
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
50 24 35 42
Growth
56 6 19 95
Safety Safety
90 93 88 75
Combined
82 43 38 92
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
51 26 33 40
Price vs. Earnings (P/E)
28 40 38 49
Price vs. Book (P/B)
29 19 22 17
Dividend Yield
63 58 63 72
Value
50 24 35 42
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
66 12 4 74
Profit Growth
44 12 18 92
Capital Growth
19 26 19 31
Stock Returns
66 24 98 96
Growth
56 6 19 95
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
64 80 76 57
Refinancing
59 44 47 42
Liquidity
86 95 100 76
Safety Safety
90 93 88 75

Similar Stocks

Discover high‑ranked alternatives to Laboratorios Farmaceuticos Rovi and broaden your portfolio horizons.

STMicroelectronics

PAR:STMPA
Country: Netherlands
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Grifols

MCE:GRF
Country: Spain
Industry: Biotechnology
Size: X-Large
Full Stock Analysis

Krka

LJU:KRKG
Country: Slovenia
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Ambev

SAO:ABEV3
Country: Belgium
Industry: Brewers
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This stock offers a high growth opportunity with safe financing and positive sentiment. It is typically expensive (low Value Rank), as investors pay a premium for high performance. It is for growth-focused investors comfortable paying a premium for a stock with strong future momentum.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews